Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN

Market Cap$453.51M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Myriad Genetics, Inc.Myriad Genetics, Inc.-3.9--16%0.50.2
$11.00

Target Price by Analysts

126.3% upsideMyriad Genetics Target Price DetailsTarget Price
$-8.81

Current Fair Value

281.3% downside

Overvalued by 281.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$453.51 Million
Enterprise Value$500.91 Million
Dividend Yield$0 (0%)
Earnings per Share$-3.18
Beta1.85
Outstanding Shares90,900,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-3.86
PEG6.03
Price to Sales0.54
Price to Book Ratio0.61
Enterprise Value to Revenue0.61
Enterprise Value to EBIT-4.52
Enterprise Value to Net Income-5
Total Debt to Enterprise0.29
Debt to Equity0.2

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Myriad Genetics, Inc.

2,600 employees
CEO: R. Bryan Riggsbee

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...